Genovis ABOSTO:GENO +0.52%84 Net Margin % is 12.71% as of Mar. 2026, which is 5% below its 10-year median of 13.36. GuruFocus rates OSTO:GENO with a GF Score™ of 84/100 and a GF Value™ of kr28.45 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Genovis AB ranks better than 86.46% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Genovis AB's Net Income for the
three
months ended in Mar. 2026 was kr4.3 Mil. Genovis AB's Revenue for the
three
months ended in Mar. 2026 was kr33.5 Mil. Therefore, Genovis AB's net margin for the quarter that ended in Mar. 2026 was 12.71%.
The historical rank and industry rank for Genovis AB's Net Margin % or its related term are showing as below:
OSTO:GENO'
s Net Margin % Range Over the Past 10 Years
Min: -81.06 Med: 13.36 Max: 38.87
Current: 18.67
OSTO:GENO's Net Margin % is ranked better than 86.46% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs OSTO:GENO: 18.67
Genovis AB (OSTO:GENO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Genovis AB Net Margin % Related Terms
Genovis AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Genovis AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GENO vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Genovis AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Genovis AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (OSTO:GENO) has a Net Margin % of 12.71% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Genovis AB and its competitors. This is near median its historical median of 13.36. According to the industry distribution chart, Genovis AB ranks #128 out of 945 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Genovis AB's Net Margin % too high?
Genovis AB's current Net Margin % of 12.71% is near median its 10-year median of 13.36. Based on the distribution chart, Genovis AB ranks #128 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovis AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #128 out of 945 companies for Net Margin %. This places Genovis AB in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Genovis AB and its competitors. Genovis AB's current Net Margin % is 12.71%, which is near median its own 10-year median of 13.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Significantly Undervalued. The stock's GF Value™ is kr28.45, compared to a current price of kr19.46 — trading 31.6% below its estimated fair value. The current Net Margin % is 12.71%, which is near median its 10-year median of 13.36. Genovis AB's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current Net Margin % is 12.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr19.46 is trading 31.6% below its estimated GF Value™ of kr28.45.
GuruFocus considers Genovis AB to be Significantly Undervalued.
Key valuation signals for OSTO:GENO:
Net Margin %: 12.71% (near median its 10-year median of 13.36)
GF Value™: kr28.45 vs. price of kr19.46 (31.6% below fair value)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
84GF Score
Get the complete analysis for OSTO:GENO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
